Indications and uses
controls the symptoms of diarrhea, including Traveler's Diarrhea
controls the symptoms of diarrhea, including Traveler's Diarrhea
use enclosed dosage cup to accurately measure dosage as noted below drink plenty of clear fluids to help prevent dehydration, which may accompany diarrhea find right dose on chart. If possible, use weight to dose; otherwise, use age. adults and children 12 years and older 4 teaspoonfuls (1 dosage cup) after the first loose bowel movement; 2 teaspoonfuls (1/2 dosage cup) after each subsequent loose bowel movement; ...
(in each 5 mL teaspoonful)
Loperamide HCl 1 mg
Antidiarrheal
Do not use if you have ever had a rash or other allergic reaction to loperamide HCl Alergy alert:
if you have bloody or black stool Do not use
Ask a doctor before use if you have
taking antibiotics Ask doctor or pharmacist before use if you are
diarrhea lasts for more than 2 days Stop use and ask a doctor if
, ask a health professional before use If pregnant or breast-feeding
In case of overdose, get medical help or contact a Poison Control Center right away.
| adults and children 12 years and older | 4 teaspoonfuls (1 dosage cup) after the first loose bowel movement; 2 teaspoonfuls (1/2 dosage cup) after each subsequent loose bowel movement; but no more than 8 teaspoonfuls a day |
| children 9-11 years (60-95 lbs) | 2 teaspoonfuls (1/2 dosage cup) after the first loose bowel movement; 1 teaspoonful (1/4 dosage cup) after each subsequent loose bowel movement; but no more than 6 teaspoonfuls a day |
| children 6-8 years (48-59 lbs) | 2 teaspoonfuls (1/2 dosage cup) after the first loose bowel movement; 1 teaspoonful (1/4 dosage cup) after each subsequent loose bowel movement; but no more than 4 teaspoonfuls a day |
| children under 6 years (up to 47 lbs) | ask a doctor (not intended for use in children under 6 years old) |
alcohol (0.5%), benzoic acid, cherry flavor, glycerin, mint flavor, propylene glycol, purified water, sodium benzoate, sorbitol solution, sucrose. Citric acid may be used to adjust pH
Call 1-800-262-9010
Mon. - Thurs. 9:00 am - 4:30 pm EST,
Fri. 9:00 am - 2:30 pm EST
Serious side effects associated with use of this product may be reported to this number.
Manufactured by:
Hi-Tech Pharmacal Co., Inc.
Amityville, NY 11701
Rev. 618:05 4/12
| Class | Version | Type | Effective |
|---|---|---|---|
| LOPERAMIDE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 10f838ef-a72b-645d-80f8-e2255205c3b1 | Product name | 6 | 20240805 |
| c6f86816-7da6-43ea-8c25-ac9758311cc5 | Product name | 1 | 20220118 |
| 252e11b6-1a9a-4283-a242-df2c129c496d | Product name | 3 | 20170717 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17856-0618-1 | 2021-01-29 | C162847 | 48780-1 | ba0f9c33-47fd-a910-e053-dadaa90a0b85 | Drug Facts |
| 17856-0618-5 | 2021-01-29 | C162847 | 48780-1 | ba0f9c33-47fd-a910-e053-dadaa90a0b85 | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-0618-1 | Loperamide Hydrochloride | 10 mL in 1 CUP | SOLUTION | 10 | 5 | |
| 17856-0618-5 | Loperamide Hydrochloride | 5 mL in 1 CUP | SOLUTION | 5 | 5 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-0618 | LOPERAMIDE HYDROCHLORIDE SOLUTION [ATLANTIC BIOLOGICALS CORPS] | 5 | Legacy NDC, 2 package rows | 20191017_b0596b9c-326d-4795-b0a5-38c858af7a77.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50383-618-04 | ML - Milliliter | 50383-618 | 8b63b39a-50bc-4955-a19f-2bf658aab638 | 1 | 2012-07-24 |
| 50383-618-05 | ML - Milliliter | 50383-618 | cebec501-71fb-4138-b911-b4abaea5d479 | 1 | 2013-10-17 |
| 50383-618-06 | ML - Milliliter | 50383-618 | 4aff43b9-f08c-42f0-891d-7d579728476b | 1 | 2013-08-02 |
| 50383-618-10 | ML - Milliliter | 50383-618 | 87fa7eba-05a0-4c90-b62a-deeca64cc69a | 1 | 2013-10-17 |
| 50383-618-11 | ML - Milliliter | 50383-618 | fdcbc23c-0d0d-4c51-9133-220296523bcb | 1 | 2013-08-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | ACTIVE INGREDIENT | 77TI35393C | 4 | |
| LOPERAMIDE | ACTIVE MOIETY | 6X9OC3H4II | 4 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 4 | |
| ANHYDROUS CITRIC ACID | INACTIVE INGREDIENT | XF417D3PSL | 4 | |
| BENZOIC ACID | INACTIVE INGREDIENT | 8SKN0B0MIM | 4 | |
| CHERRY | INACTIVE INGREDIENT | BUC5I9595W | 4 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 4 | |
| MINT | INACTIVE INGREDIENT | FV98Z8GITP | 4 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 4 | |
| SODIUM BENZOATE | INACTIVE INGREDIENT | OJ245FE5EU | 4 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 4 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17856-0618 | 17856-0618-1, 17856-0618-5 |
| 50383-618 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | 77TI35393C | ACTIB |
| ALCOHOL | 3K9958V90M | IACT |
| ANHYDROUS CITRIC ACID | XF417D3PSL | IACT |
| BENZOIC ACID | 8SKN0B0MIM | IACT |
| CHERRY | BUC5I9595W | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| MINT | FV98Z8GITP | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| SORBITOL | 506T60A25R | IACT |
| SUCROSE | C151H8M554 | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ALCOHOL | ALCOHOL | 3K9958V90M | INJECTION, SOLUTION / SUBCUTANEOUS | 6.1 %v/v | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRA-ARTICULAR | 45 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | ENEMA / RECTAL | 60 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / VAGINAL | 6.4 %w/w | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 48 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | PASTE / DENTAL | 0.5 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, COATED / ORAL | 12.96 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION / INFILTRATION | 0.02 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / RECTAL | 90400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / TOPICAL | 4522 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CREAM, AUGMENTED / TOPICAL | 15 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET / BUCCAL | 30 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | POWDER, FOR SUSPENSION / ORAL | 570 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY / SUBLINGUAL | 36 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | PASTE / DENTAL | 14.6 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| SORBITOL | SORBITOL | 506T60A25R | AEROSOL, FOAM / TOPICAL | 4.95 %w/w | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRALESIONAL | 45 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | CREAM / TOPICAL | 6 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY, METERED / NASAL | 240 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, COATED / ORAL | 14.21 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYSTEM / TOPICAL | 4200 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | CONCENTRATE / INTRAVENOUS | ADJ PH | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, EXTENDED RELEASE / ORAL | 9 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / TOPICAL | 5.28 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | GRANULE / ORAL | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | GUM, CHEWING / BUCCAL | 5110 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | CONCENTRATE / ORAL | 600 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO / TOPICAL | 8 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | GEL, METERED / TOPICAL | 541 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | GRANULE, FOR SUSPENSION / ORAL | 120 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL / TOPICAL | 561 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / VAGINAL | NA | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / RESPIRATORY (INHALATION) | 5 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SOLUTION / ORAL | 29268 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | CONCENTRATE / BUCCAL | 679 mg/1ml | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | PASTE, DENTIFRICE / DENTAL | 0.5 %w/w | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | ELIXIR / ORAL | 90 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A074352-001 | LOPERAMIDE HYDROCHLORIDE | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A074352-001 | LOPERAMIDE HYDROCHLORIDE | 1MG/5ML | SOLUTION / ORAL | 1995-11-17 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5a00eb66-d425-467c-a2d8-6e82a701348b | b0596b9c-326d-4795-b0a5-38c858af7a77 | 2019-10-16 | Warnings | 5a00eb66-d425-467c-a2d8-6e82a701348b b0596b9c-326d-4795-b0a5-38c858af7a77 |
Adverse event summaries are temporarily unavailable. Other product information remains available.